

## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 21 U.S.C. §355 (n)(4)

Michael Perry, M.D.

**Committee:** Oncologic Drugs Advisory Committee

**Meeting Date:** September 6-7, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to (1) New Drug Application (NDA) 21-874, proposed trade name Genasense (oblimersen sodium) Injection, sponsored by Genta Inc., for use in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia who are refractory to or have relapsed after therapy with fludarabine; (2) NDA 20-287, Fragmin (dalteparin sodium injection), sponsored by Pfizer, Inc., for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)) to reduce the recurrence of VTE in patients with cancer; and (3) NDA 21-660, Abraxane (paclitaxel protein-bound particles for injectable suspension)(albumin-bound), sponsored by Abraxis BioScience, Inc., including trial design issues for adjuvant treatment of node-positive breast cancer, I am eligible to receive a waiver under 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Sponsor and competitor for issue 2 and competitor for issue 3	Valued at less than \$5,001
Stock	Competitor for issues 1 and 3	Valued between \$5,001 and \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.

\_\_\_\_\_  
/s/  
Signature

\_\_\_\_\_  
8/3/06  
Date